IN THE NEWS

BOTHELL, Wash. -- Cardiac Science Corporation, a global leader in advanced cardiac monitoring and external defibrillation products, announced today that Nederlandse Spoorwegen (NS), the national train operator in the Netherlands, has placed an order for 220 Powerheart^® G3 Automatic automated external defibrillators (AEDs).

NS operates the rail system throughout the Netherlands, which transports more than one million passengers each day.

“AEDs should be easily accessible in any place that is used heavily by the public, and a train station is no exception,” said Garry Norris, Cardiac Science vice president, marketing. “Cardiac Science is experienced at creating heart-safe environments in transport systems.  More than 350 Powerheart AEDs are deployed in railway stations in England, and a significant number of Powerheart AEDs are deployed in several high-traffic, mass-transit environments in the United States.

“According to the American Heart Association, the chances of surviving a sudden cardiac arrest diminish approximately seven to 10% with each minute that passes following the event,” Mr. Norris continued.  “On a moving train or a crowded station where emergency personnel may not be on-hand, reliable, accessible and easy-to-use AEDs are particularly imperative.  We commend NS for taking this step to support the heart health of its passengers.” 

“The safety of our passengers and staff is a top priority,” said Mr. Senol Demirel, NS’ Occupational Health Advisor. “After a fair review of companies, we chose Powerheart because the device offers rescuers ease of use, advanced technology and reliability through extensive self testing, as well as its compatibility with European Resuscitation Council Guidelines for Resuscitation. Plus it has excellent Dutch language voice prompts.  By installing AEDs throughout the Netherlands rail system, everyone who passes through the stations can be assured that they are in a heart safe environment.”

About Powerheart

Powerheart brand automated external defibrillators provide reliable, safe, and easy to use cardiac monitoring and defibrillation technology. Powerheart AEDs feature RHYTHMx™ software which detects abnormal heart rhythms, determines whether they are life-threatening, and only delivers a shock when needed. Powerheart AEDs also feature the patented RescueReady^® technology, which automatically tests the device on a frequent basis to ensure continued functionality. Powerheart’s STAR^® Biphasic Waveform Technology provides levels of escalating energy customized to the patient.  Powerheart AEDs are used by hospitals, police and fire departments, as well as many public access facilities including major corporations, public agencies, airlines and airports, arenas, schools, hotels, casinos and consumers. For more information about Powerheart, go to www.powerheart.com.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif